a year ago

Glen Clova Scientific Secures £4 Million to Develop Autoimmune Disease Therapies

  • Glen Clova Scientific, a Scottish biotech startup developing drugs for chronic inflammatory and autoimmune disorders, has raised £4 million in a Seed round led by Norcliffe Capital

  • The investment will be used to advance preclinical development of three initial drugs: GCS001 for treatment of senile pruritus, GCS002 for atopic dermatitis and GCS003 for eczema and asthma

  • The company has developed a technology platform underpinning its product development pipeline and GCS’ technology will be exploited in several non-pharmaceutical markets through partnerships

  • DSW Ventures, TRICAPITAL Angels and Scottish Enterprise also participated in the round.

      • ProblemHealthcare

      "Patients with chronic inflammatory and autoimmune disorders often suffer from poorly met medical needs, with existing biologic drugs being expensive and complex to manufacture."

      Solution

      "Glen Clova Scientific is developing a new generation of active biologic drugs using its proprietary GCS VLP platform. This platform offers enhanced performance and a simpler, more cost-effective manufacturing process compared to existing biologic drugs. The company is focusing on three initial drugs: GCS001 for senile pruritus, GCS002 for atopic dermatitis, and GCS003 for eczema and asthma."

      Covered on